Continuum Advisory’s Neurocrine Biosciences NBIX Stock Holding History

Continuum Advisory’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.81M	Buy	44,068 +1,517	+4%	+$201K	0.56%	39
2025 Q4	$6.04M	Buy	42,551 +2,548	+6%	+$369K	0.6%	40
2025 Q3	$5.62M	Buy	40,003 +3,416	+9%	+$463K	0.59%	38
2025 Q2	$4.6M	Buy	36,587 +36,560	+135,407%	+$4.19M	0.55%	42
2025 Q1	$2.99K	Hold	27	–	–	﹤0.01%	1226
2024 Q4	$3.69K	Sell	27 -6	-18%	-$742	﹤0.01%	1211
2024 Q3	$4.05K	Buy	33 +10	+43%	+$1.37K	﹤0.01%	1218
2024 Q2	$3.17K	Hold	23	–	–	﹤0.01%	1190
2024 Q1	$3.21K	Buy	+23	New	+$3.14K	﹤0.01%	1167

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Continuum Advisory's NBIX Position: Q1 2026 in Review

Continuum Advisory increased its Neurocrine Biosciences (NBIX) stake by 3.6% in Q1 2026, buying an estimated $201K and bringing the position to 44,068 shares worth $5.81M. The position accounts for 0.56% of the portfolio, ranked #39.

Continuum Advisory first reported a position in NBIX in Q1 2024 and has held it in 9 quarters since. The position peaked at $6.04M in Q4 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Continuum Advisory held 44,068 shares of Neurocrine Biosciences worth $5.81M as of Q1 2026.
Continuum Advisory bought 1,517 Neurocrine Biosciences shares in Q1 2026, an estimated $201K.
Neurocrine Biosciences made up 0.56% of Continuum Advisory's portfolio in Q1 2026, its #39 holding.
Continuum Advisory first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 9 quarters since.
Continuum Advisory's Neurocrine Biosciences position peaked at $6.04M in Q4 2025.
695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Continuum Advisory's 13F filing for Q1 2026, filed 22 Apr 2026.